Lonza, Integral Molecular join forces on risk assessment

By The Science Advisory Board staff writers

April 27, 2022 -- Lonza and Integral Molecular are collaborating on a strategy to better assess the risks of off-target binding of biologic drug candidates because unwanted immunogenicity can have severe consequences for patients and jeopardize drug development programs.

Lonza's Early Development Services focuses on cell-based assays to evaluate the activity of biologic therapies upon binding. Integral Molecular de-risks therapeutic molecules by detecting off-target binding liabilities using its Membrane Proteome Array platform.

The collaboration will cover the full spectrum of in vitro immunosafety testing and allow customers to save time and resources by identifying and mitigating potential clinical risks earlier on, the firms said.

Integral Molecular launches protein engineering platform
Integral Molecular announced the launch of its proprietary protein engineering platform, GeneCanvas, for the optimization of transgenes and other elements...
Lonza dedicates manufacturing suite to Altimmune's COVID-19 vaccine
Altimmune has expanded its previously established manufacturing collaboration with Lonza for AdCOVID, Altimmune's single-dose, intranasal COVID-19 vaccine...
Integral Molecular, Optimeos partner on long-lasting antibody therapeutics
Integral Molecular and Optimeos Life Sciences have partnered to develop novel antibody therapeutics using long-acting, sustained delivery formulations.
Integral Molecular touts Pa. grant to advance COVID-19 research
Integral Molecular was awarded over $520,000 from the state of Pennsylvania to leverage its technologies in COVID-19 research. The grant will enable the...

Copyright © 2022 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter